Backup Slide Hypertriglyceridemia

1
Backup SlideHypertriglyceridemia

• Denise Cook, M.D.

2
HypertriglyceridemiaPivotal Trials
Study Tazarotene N 166 Tazarotene N 166 Tazarotene N 166 Tazarotene N 166 Tazarotene N 166 Placebo N171 Placebo N171 Placebo N171 Placebo N171 Placebo N171 Placebo N171
048P Mild 2.3-2.79 mmol/L Moderate 2.8-5.6 mmol/L Moderate 2.8-5.6 mmol/L Severe gt5.61 mmol/L Total Mild 2.3-2.79 mmol/L Moderate 2.8-5.6 mmol/L Moderate 2.8-5.6 mmol/L Severe gt5.6 mmol/L Severe gt5.6 mmol/L Total
048P 22 (13.3) 14 (8.4) 14 (8.4) 3 (1.8) 39 (23.5) 15 (8.8)
049P Tazarotene N 182 Tazarotene N 182 Tazarotene N 182 Tazarotene N 182 Tazarotene N 182 Placebo N187 Placebo N187 Placebo N187 Placebo N187 Placebo N187 Placebo N187
049P 14 (7.7) 9 (4.9) 2 (1.1) 2 (1.1) 25 (13.7) 25 (13.4) 25 (13.4)
p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined p 0.0022 for total combined